Compare AIRS & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIRS | PLX |
|---|---|---|
| Founded | 2012 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.4M | 207.1M |
| IPO Year | 2021 | 1996 |
| Metric | AIRS | PLX |
|---|---|---|
| Price | $1.23 | $2.55 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.50 | N/A |
| AVG Volume (30 Days) | 826.2K | ★ 840.6K |
| Earning Date | 11-06-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | ★ $151,818,000.00 | $52,744,000.00 |
| Revenue This Year | N/A | $55.77 |
| Revenue Next Year | $2.65 | N/A |
| P/E Ratio | ★ N/A | $9.57 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.16 | $1.65 |
| 52 Week High | $12.00 | $3.19 |
| Indicator | AIRS | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 24.50 | 42.21 |
| Support Level | N/A | $2.21 |
| Resistance Level | $3.31 | $2.75 |
| Average True Range (ATR) | 0.13 | 0.10 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 8.57 | 7.41 |
AirSculpt Technologies Inc is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results. Its proprietary and patented AirSculpt method is minimally invasive because it requires no needle, no scalpel, no stitches, and no general anesthesia. It offers fat removal procedures across treatment areas and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips or other areas and do not require silicone or foreign materials to be implanted. Its segment is direct medical procedure services.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.